Jaguar Health, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
JAGX Nasdaq 2830 jaguar.health

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Jaguar Health, Inc.

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient - Jun 30th, 2025 7:00 am
Jaguar Health to pursue approval of Canalevia in EU for general diarrhea in dogs - Jun 26th, 2025 7:15 am
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset - Jun 26th, 2025 7:00 am
Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs - Jun 25th, 2025 7:00 am
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 - Jun 24th, 2025 2:15 pm
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - Jun 17th, 2025 7:00 am
Presenting on Emerging Growth Conference 83 Day 2 on June 18; Register to live stream - Jun 17th, 2025 5:00 am
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Jun 11th, 2025 8:00 am
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series - Jun 9th, 2025 2:15 pm
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer - Jun 9th, 2025 7:00 am
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series - Jun 6th, 2025 7:00 am
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - May 21st, 2025 6:00 am
First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID) - May 20th, 2025 7:15 am
Jaguar Health Inc (JAGX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Promising ... - May 16th, 2025 1:12 am
Jaguar Health Reports First Quarter 2025 Financials - May 15th, 2025 12:30 pm
Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates - May 14th, 2025 7:00 am
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs - May 8th, 2025 7:30 am
Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts - May 7th, 2025 7:15 am
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients - Apr 30th, 2025 6:15 am
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) - Apr 29th, 2025 2:15 pm